Background. Clarithromycin is frequently used to treat community-acquired pneumonia in elderly persons. Like erythromycin, it may interact with other drugs by interfering with metabolism by cytochrome P450 enzymes and with the P-glycoprotein transporter system. Colchicine, used for treatment of acute gout and for prophylaxis, may cause bone marrow toxicity. It is metabolized by CYP3A4 and is transported by P-glycoprotein. Initial case reports suggested potentially fatal interactions between clarithromycin and colchicine.
quently have major underlying medical illnesses, such as hypertension, ischemic heart disease, congestive heart failure, chronic renal insufficiency, and hyperuricemia. Many of them developed acute gout during hospitalization as a result of a variety of precipitating factors, such as dehydration, diuretics, and sepsis. Colchicine has often been prescribed as a rapidly effective and inexpensive treatment for gout. We previously described 2 patients who developed fatal drug interactions, characterized by marrow hypoplasia, after concomitant therapy with clarithromycin and colchicine [3] . Review of the literature suggested a possible interaction between clarithromycin and colchicine at the cellular level that involved cytochrome P450 metabolism and P-glycoprotein transportation. Such interactions affect the oral bioavailability, metabolism, and excretion of colchicine. Therefore, a retrospective study was undertaken to define the incidence and risk factors for adverse outcomes in patients who were treated with these 2 agents during hospitalization.
PATIENTS AND METHODS
This study was conducted in a 1300-bed tertiary care teaching hospital that has a computer system at the pharmacy that records daily prescriptions for all hospitalized patients. The clinical management system (CMS) was installed and put into full use in September 1997. Patient data, including hospital identification numbers, the durations of hospitalization, and the dates of prescription of colchicine and macrolides, as well as other drugs, can be retrieved from this database. All patients who were prescribed macrolides and colchicine were recruited for this study. Their clinical records and laboratory investigation results were retrieved for detailed analysis. A patient's demographic characteristics and underlying diseases, the diagnosis at admission, the dosage of macrolides and colchicine, the dates of administration, the indication for colchicine, adverse effects, laboratory findings during hospitalization, and outcomes were recorded. The prescriptions of all recruited patients were scrutinized for drugs known to cause pancytopenia and any drugs known to produce potentially fatal drug interactions with macrolides and colchicine, such as ciprofloxacin, doxycycline, isoniazid, protease inhibitors, azole antifungals, diclofenac, imatinib, propofol, quinidine, and verapamil. Results of microbiological examinations for community-and hospital-acquired sepsis were retrieved and reviewed. Case-control comparisons were made between patients who received concomitant therapy with colchicine and macrolides and patients who did not. Among the patients who received concomitant therapy, we then compared those who died within 28 days after hospital admission with those who survived, and we compared those who developed pancytopenia with those who did not. Concomitant therapy was defined as the receipt of clarithromycin and colchicine with a period of overlap, whereas sequential therapy was defined as simply the receipt of clarithromycin and colchicine during the same admission. For the clinical presentation and investigation findings, fever was defined as a body temperature of 138ЊC, renal insufficiency was defined as a creatinine level of 1140 mmol/L, and diarrhea was defined as bowel opening at a frequency of у3 times daily. In addition, baseline alanine transaminase (ALT) levels that were у2 times the upper limit of normal (180 U/L) were recorded. Pancytopenia was defined as a neutrophil count of ! cells/L, a hemo-9 2.0 ϫ 10 globin level of !12 g/dL for women and !14g/dL for men, and a platelet count of ! platelets/L. Adverse outcomes 9 150 ϫ 10 included development of pancytopenia, death, or both. The premorbid status of each patient was quantitatively assessed using the Charlson index [4] . The Charlson index contains 19 categories of comorbidity that are defined using International Classification of Diseases, Ninth Edition, Clinical Modification diagnosis codes. The overall comorbidity score reflects the cumulative likelihood of mortality within 1 year.
We compared the clinical characteristics, investigation results, and adverse outcomes of these patients by Fisher's exact test, for categorical variables, and Student's t test, for continuous variables. A 2-tailed P value of !.05 was considered statistically significant. For nonparametric variables, the MannWhitney U test was used. Statistically significant risk factors identified on univariate analysis were further analyzed by linear regression to identify independent risk factors associated with ). The baseline characteristics of the 116 patients and P p .04 their outcomes are shown in figure 1.
The concomitant group had an overall mortality rate of 10.2% (9 of 88 patients), whereas the mortality rate among the sequential group was 3.6% (1 of 28 patients) (table 1). The demographic characteristics, clinical profiles, baseline investigative findings, and outcomes were not statistically different between the 2 groups. In the concomitant group, 9 patients (11.39%) developed pancytopenia (table 2) . Comparison by univariate analysis showed that significantly more patients who developed pancytopenia had an ALT level у2 times the upper limit of normal ( ) than did patients without pancyto-P p .01 penia and that patients who developed pancytopenia had a significantly higher median total dose of colchicine ( ), P ! .01 higher median number of days of concomitant therapy (P ! ), and higher mortality rate ( ) were indepen-P ! .001 dently associated with death.
The clinical profiles of all patients with pancytopenia were tabulated in table 4. Their ages ranged from 55 to 92 years, with a ratio of men to women of 1:1. Eleven patients were admitted for community-acquired pneumonia, and 1 was admitted for acute gastroenteritis. The number of days of con- comitant administration of clarithromycin and colchicine ranged from 1 to 10 days, with a median of 3 days. For the 7 patients with pancytopenia, the hematological abnormalities were most severe at 9-18 days (median, 10 days) after the first dose of concomitant administration. The terminal event for 7 patients was pneumonia, but 2 of those patients had acute renal failure with preexisting chronic renal failure (i.e., "acute-onchronic renal failure"), 1 had congestive heart failure, and 1 had multiple organ failure. Biopsy of a bone marrow specimen obtained from 1 of the patients who died showed moderately hypocellular marrow with left-shifted granulopoieisis and no abnormal infiltration. Postmortem examination of another patient showed agranulocytosis and massive hepatic necrosis. None of these 9 patients were given other drugs that have the potential to cause pancytopenia either by themselves or through drug-drug interactions. Microbiological findings are summarized in table 5.
DISCUSSION
Macrolides have long been known to be a substrate, in addition to being a reversible inhibitor, of the cytochrome P450 enzyme CYP3A4 [5] [6] [7] . Recently, they have also been found to be important inhibitors of the P-glycoprotein transporter system [8] [9] [10] [11] . These properties lead to important effects of drug interactions due to either increased macrolide levels or increased levels of other concomitantly administered drugs as a result of competition for the same pathway of metabolism or excretion. A recent report described the development of serious cardiac arrhythmias associated with concomitant use of erythromycin and various inhibitors of CYP3A4 [12] . In addition, potentially fatal drug interactions with drugs such as clozapine, disopyramide, and cisapride that are the result of their decreased metabolism due to inhibition of CYP3A4 by macrolides, are also commonly reported in the literature [13] [14] [15] . Colchicine, an effective and commonly prescribed drug for the treatment of gout and familial Mediterranean fever, is metabolized via the enzyme CYP3A4, in addition to being a substrate of the Pglycoprotein [16] [17] [18] . Despite the expected drug interactions between macrolides and colchicine, only 4 cases of serious interaction were found in our review of the literature (table 6) [19] [20] [21] [22] . Except for 1 case of deliberate ingestion of a megadose of colchicine (40 mg bolus) in a suicide attempt [22] , the patients received a maintenance dosage of colchicine (range, 1-1.5 mg/day) for treatment of familial Mediterranean fever [19] [20] [21] . It is noteworthy that those 3 patients had chronic renal insufficiency. All 3 of them developed features of colchicine toxicity, manifesting as gastrointestinal symptoms (abdominal pain, vomiting, and diarrhea), fever, and pancytopenia, shortly after concomitant administration of macrolides (median time to presentation, 8 days; range, 7-19 days) for management of a variety of conditions. The duration of concomitant therapy ranged from 4 to 14 days (median, 7 days). In a patient who died as a result of multiorgan failure, bone marrow examination revealed the presence of bone marrow hypocellularity [20] . The colchicine level was markedly elevated in at least 1 of the patients (22 ng/mL) [21] . In our retrospective study, comparison was made between patients who received concomitant therapy and patients who received sequential therapy (table 1). Despite the fact that a higher percentage of patients in the concomitant group than in the sequential group developed pancytopenia (10.2% vs. 0%) and that there was a higher mortality rate in the concomitant group than in the sequential group (10.2% vs. 3.6%), the differences were not statistically significant. One possible reason is the relatively small sample size, which is a limitation of the study. We therefore compared the patients in the concomitant group who developed pancytopenia with those who did not and also compared the survivors and the nonsurvivors in the concomitant group. Longer overlapped therapy, baseline renal impairment, and development of pancytopenia were independently associated with mortality. This confirmed the findings of the case reports mentioned above. In contrast to the patients described in the literature, 11 of our 12 patients who had adverse outcomes were admitted for community-acquired pneumonia and were initially prescribed macrolide therapy (table 4 and figure 1 ). During their hospital stay, these patients developed acute gouty attack secondary to various conditions and, in addition, were administered colchicine. Bone marrow examination for 2 of the patients with pancytopenia revealed hypocellular marrow, similar to the findings for the cases described previously. Despite the fact that none of these patients had their serum colchicine levels measured, the clinical features and disease progressions were, in retrospect, strongly suggestive of colchicine toxicity [23] [24] [25] . Yet none of the physicians in charge of the aforementioned patients suspected this condition while the patients were being cared for in the hospital. It was NOTE. AAA, abdominal aortic aneurysm; AOC renal failure, acute renal failure in a patient with chronic renal failure (i.e., "acute-on-chronic renal failure"); BPH, benign prostatic hypertrophy; CBP, complete blood picture; CHF, congestive heart failure; COAD, chronic obstructive airway disease; CRF, chronic renal failure; DM, diabetes mellitus; DVT, deep venous thrombosis; HT, hypertension; IHD, ischemic heart disease; MI, myocardial infarction; NA, not applicable; OA, osteoarthritis; PTB, pulmonary tuberculosis. 
Pseudomonas aeruginosa 2
Pseudomonas species 2 Stenotrophomonas maltophilia 1
Streptococcus pneumoniae 1
Urine culture C. albicans 2
Candida glabrata 3 Candida species 5
Enterobacter species 1 recently reported that the adjusted rate of sudden death from cardiac causes was 5 times as high (incidence rate ratio, 5.35; 95% CI, 1.72-16.64; ) among those who used CYP3A P p .004 inhibitors and erythromycin concurrently than among those who did not [12] . However, our study demonstrated that, in patients who received concomitant therapy with colchicine and clarithromycin and who developed pancytopenia, the risk of death was increased 25-fold (RR, 25; 95% CI, 5.19-125.3; ). P ! .001
The metabolism and deposition of colchicine have been reviewed extensively [26] [27] [28] . In brief, after absorption from the small bowel, the drug underwent substantial presystemic metabolism, leading to a bioavailablity of only 25%-50%. Thirty percent of the absorbed colchicine was distributed to tissues, including the gastrointestinal tract, muscle, heart, and spleen, and to WBCs [29] . Colchicine was particularly concentrated in WBCs, which might have led to subsequent marrow suppression in the case of overdose. Twenty percent of the colchicine was excreted in the urine as unchanged drug, whereas the other 50% was metabolized by the cytochrome P450 system-mainly involving the CYP3A4 system in the liver-by deacetylation, demethylation, and glucuronidation [30] . Clarithromycin and other macrolides could potentially alter the absorption, metabolism, and excretion of colchicine via different mechanisms [31] [32] [33] [34] [35] [36] [37] . Clarithromycin can increase oral bioavailability by increasing the absorption and presystemic metabolism of colchicine through inhibition of the P-glycoprotein in the enterocytes. It can decrease hepatic metabolism and clearance of colchicine by acting as a slow reversible inhibitor of the cytochrome P450 system in the liver. In addition, clarithromycin could impair the excretion of colchicine via the hepatic metabolism and renal excretion-again, by interfering with the P-glycoprotein. Under normal circumstances, the excretion of colchicine in the urine could increase to compensate for reduced liver metabolism in patients with liver disease or to counteract the effects of the administration of drugs that interact with the cytochrome P450 system [38] . However, this mechanism would be hampered if the patients already had concomitant renal insufficiency, leading to an accumulation of colchicine and the subsequent fatal outcomes. Colchicine toxicity can be divided into 3 sequential stages [39] . The first stage occurs during the first 24 h after ingestion and is dominated by the aforementioned gastrointestinal symptoms. The second stage (24-72 h after ingestion) is dominated by multiorgan failure. This includes bone marrow failure, renal failure, adult respiratory distress syndrome, arrhythmias, disseminated intravascular coagulation, and neuromuscular disturbances. Recovery of bone marrow, with rebound leukocytosis; resolution of organ system derangement; and development of alopecia characterize the third phase, if the patient survives the toxicity. Treatment is mainly supportive, with daily subcutaneous in- jections of granulocyte-colony stimulating factor (G-CSF) during severe leukopenia. Anecdotal experience with the use of colchicine-specific Fab fragments for treatment of severe colchicine toxicity has also been reported, but these antibodies are not readily available [40] .
In our cohort, 6 of 10 patients died as a result of pneumonia, and 5 of them developed pancytopenia. G-CSF (300 mg) was administered subcutaneously to 1 of the 5 patients with pancytopenia. The other 4 patients reportedly died as a result of acute chronic renal failure (2 patients), congestive heart failure (1 patient), and multiorgan failure (1 patient). These deaths could be explained by the direct toxic effect of colchicine on the various organs, including the liver, kidney, and bone marrow, especially for patients who had chronic renal insufficiency before hospital admission. In our hospital, clarithromycin is the most commonly prescribed macrolide, because it has better gastrointestinal tolerance than erythromycin and because it was introduced earlier into the local market than azithromycin was. In conclusion, clarithromycin and colchicine should not be prescribed concomitantly, especially for patients who have chronic renal insufficiency. It is important to alert the pharmacy service to intervene on dual prescriptions. Other strong inhibitors of CYP3A4 should similarly be avoided. If a macrolide must be prescribed with colchicine, azithromycin should be considered, because it is mainly excreted unchanged in the bile and has no effect on cytochrome P450 metabolism and the Pglycoprotein transporter system [41, 42] .
